Elan has assay to identify Tysabri patients at risk of PML

Elan Plc said that it has developed an assay that appears to identify those multiple sclerosis patients on Tysabri (natalizumab) who are at risk of developing the rare brain disease, progressive multifocal leukoencephalopathy (PML).